Japan Pharmaceuticals & Healthcare Report

Published: December 10 2009 Quarterly   

Report Downloads

  • Independent 5-year pharmaceutical and healthcare industry forecasts for Japan.
  • Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Japanese pharmaceutical and healthcare industry.
  • Competitive intelligence, Japanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Japanese market.
Was $1030.00
Now $875.00   You Save $155.00 (15%)

Order Now

Related Products

Japan Products

Japan Business Forecast Report

The Japan Business Forecast Report provides essential macroeconomic, political and financial analysis for companies doing business in Japan. Read More

Pharmaceuticals & Healthcare Products

India Pharmaceuticals & Healthcare Report

The India Pharmaceuticals & Healthcare Report has been researched at source and features the latest available data and forecasts to end-2012, covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade. Read More

South Korea Pharmaceuticals & Healthcare Report

The South Korea Pharmaceuticals & Healthcare Report has been researched at source and features the latest available data and forecasts to end-2012, covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade. Read More

Report Description

The Japan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end-2014 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Japan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Japanese pharmaceutical and healthcare industry.

Key Benefits of Report

  • Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Japan to test other views – a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.
  • Target Business Opportunities & Risks in the Japanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Japan.
  • Exploit The Latest Competitive Japanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Japan.

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end-2014 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
  • Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
  • OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
  • Generics market (US$bn)/ as % of total market
  • Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Read about our other Pharmaceuticals & Healthcare Reports

Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research


BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.